<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE307nnn/GSE307525/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307525</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia [iLS-bulkRNA]</name><description>NUTM1-rearrangement (NUTM1-r) defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A-rearrangements (KMT2A-r), yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-r leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5' fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment towards the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially-transplantable prepro-B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-r leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.</description><dates><publication>2026/04/22</publication></dates><accession>GSE307525</accession><cross_references><GSM>GSM9225983</GSM><GSM>GSM9225993</GSM><GSM>GSM9225982</GSM><GSM>GSM9225981</GSM><GSM>GSM9225992</GSM><GSM>GSM9225991</GSM><GSM>GSM9225980</GSM><GSM>GSM9225990</GSM><GSM>GSM9225979</GSM><GSM>GSM9225989</GSM><GSM>GSM9225978</GSM><GSM>GSM9225988</GSM><GSM>GSM9225977</GSM><GSM>GSM9225976</GSM><GSM>GSM9225987</GSM><GSM>GSM9225986</GSM><GSM>GSM9225985</GSM><GSM>GSM9225984</GSM><GPL>24247</GPL><GSE>307525</GSE><taxon>Mus musculus</taxon><PMID>[41460961]</PMID></cross_references></HashMap>